![Rakesh Marwah](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Dr. Rakesh Marwah, MD, is a Chief Executive Officer, Portfolio Manager & Founder of KRI Capital.
He brings 20+ years of healthcare investing expertise alongside 25+ years of medical and industry experience.
Before KRI, he spent nearly 20 years at Palo Alto Investors, advancing from research associate to investment professional.
In parallel, he served as Clinical Faculty at Stanford University Medical Center for almost 15 years and, since 2022, as Adjunct Assistant Professor at UT Southwestern Medical Center.
Earlier in his career, he led start-up and product-development engagements across the spectrum of healthcare as a consultant.
At Palo Alto Investors, he co-led investments such as Onyx (acquired by Amgen), Auxilium (acquired by Endo), Abiomed (acquired by Johnson & Johnson), Immunomedics (acquired by Gilead), and Provention Bio (acquired by Sanofi), and others.
Alongside this medical experience, he leverages his investing expertise and network to source and diligence ideas, engage with management teams and KOLs, drive investment execution and portfolio construction.
Dr. Marwah received his bachelor of science in biology and his doctor of medicine degree from UC Irvine.
Postes actifs de Rakesh Marwah
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Rakesh Marwah
| Sociétés | Poste | Fin |
|---|---|---|
Palo Alto Investors LP
 Palo Alto Investors LP Investment ManagersFinance PAI invests principally, but not exclusively, in equity and equity-related securities that are traded publicly in US markets and issued by companies primarily in the healthcare industry. The firm conducts deep, fundamental research to identify long-term investments. They look beyond consensus opinion and uncover opportunities by employing a disciplined, bottoms-up approach. PAI avoids the crowds by focusing on companies that could be overlooked due to their limited impact on major indices. | Analyst-Equity | 01/06/2025 |
Formation de Rakesh Marwah
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
3
Relations au 1er degré
2
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Palo Alto Investors LP
Palo Alto Investors LP Investment ManagersFinance PAI invests principally, but not exclusively, in equity and equity-related securities that are traded publicly in US markets and issued by companies primarily in the healthcare industry. The firm conducts deep, fundamental research to identify long-term investments. They look beyond consensus opinion and uncover opportunities by employing a disciplined, bottoms-up approach. PAI avoids the crowds by focusing on companies that could be overlooked due to their limited impact on major indices. | Finance |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
